Authors: Sharon Salt, Editor
This week in industry we’re covering some of the biggest stories that have made the headlines, including the decision to discontinue the elenbecestat trials for Alzheimer’s disease and Toca 511/Toca FC failing to meet their primary endpoint for high-grade glioma.
In addition to this, Novartis (Basel, Switzerland) have presented their findings from an earlier report where they indicated that ofatumumab is superior to Aubagio® for relapsing multiple sclerosis (MS). Discover more about our selection of this week’s highlights below (click to navigate):
- Elenbecestat trials to be discontinued for early Alzheimer’s disease
- Ofatumumab is superior to Aubagio for relapsing multiple sclerosis
- Toca 511 and Toca FC fail to meet primary endpoint for high-grade glioma
Elenbecestat trials to be discontinued for early Alzheimer’s disease
This decision was based on a recommendation made by the Data Safety Monitoring Board, which indicated that these trials be discontinued due to an unfavorable risk–benefit ratio. Detailed data of these studies will be presented at future medical meetings.